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Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
The prefrontal cortex (PFC) receives extensive dopaminergic
inputs and is particularly impaired in schizophrenia (Gold-
man-Rakic et al. 2004). At the subcellular level, dendritic
spines enriched with D1 and NMDA receptors in PFC
pyramidal neurons are common targets of both glutamatergic
and dopaminergic axons and thus providing the cellular basis
for dopamine (DA)-glutamate interactions (Cepeda and
Levine 2006). DA functions are mediated by D1 class (D1/
D5) and D2 class (D2, D3 and D4) G-protein coupled
receptors (Missale et al. 1998). Previous studies indicated
that NMDA receptor-mediated current is differentially reg-
ulated by dopamine receptors, with enhancement by D1
(Cepeda et al. 1998; Seamans et al. 2001; Flores-Hernandez
et al. 2002) and suppression by D2 (Zheng et al. 1999; Li
et al. 2009). The D1-mediated enhancement of NMDA
receptors was observed in various brain regions (Chergui
and Lacey 1999; Wang and O’Donnell 2001; Chen et al.
2004; Hallett et al. 2006; Gao and Wolf 2008; Tong and
Gibb 2008; Varela et al. 2009). Despite the overwhelming
evidence regarding D1 and NMDA receptors in synaptic
functions, the molecular mechanisms underlying the D1
modulation of NMDA receptors remain elusive, particularly
in prefrontal neurons.
It is widely accepted that D1 receptors are positively
coupled to Gs to regulate NMDA receptors via cAMP-
protein kinase A (PKA)-DARPP-32 (dopamine- and cyclic
AMP-regulated phosphoprotein of 32 kDa) cascade (Blank
et al. 1997; Cepeda et al. 1998; Snyder et al. 1998;
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Abstract
Understanding the interaction between dopamine and gluta-
mate, particularly the interaction of dopamine and NMDA
receptors, may enable a more rational approach to the treat-
ment of schizophrenia, drug addiction, and other psychiatric
disorders. We show that, in prefrontal cortical neurons,
dopamine D1-induced enhancement of NMDA receptor func-
tion depends on rapid insertion of new NMDA receptor 2B
subunits on the synaptic surface. Protein kinase A (PKA)
inhibitor, but not protein kinase C (PKC) inhibitor, completely
blocked dopamine D1 agonist SKF-81297-induced increase of
the total expression of NMDA receptors. Furthermore, SKF-
81297 failed to alter the surface expression and synaptic
insertion of NMDA receptors in the presence of PKA inhibitor,
phospholipase C inhibitor, PKC inhibitor, or Src family kinase
inhibitor. Our data suggest that D1-mediated enhancement of
NMDA current depends on the NMDA receptor trafficking
through rapid synaptic insertion and both PKA and PKC sig-
naling pathways play important roles in the regulatory pro-
cess. Although both PKA and PKC mediate the D1-induced
enhancement of NMDA receptors, the phospholipase C-PKC-
Src pathway is only required for surface expression and new
synaptic insertion of NMDA receptors.
Keywords: D1 receptors, dopamine, glutamate, NMDA
receptors, prefrontal cortex, psychiatric disorders.
J. Neurochem. (2010) 114, 62–73.
JOURNAL OF NEUROCHEMISTRY | 2010 | 114 | 62–73 doi: 10.1111/j.1471-4159.2010.06720.x
62 Journal Compilation  2010 International Society for Neurochemistry, J. Neurochem. (2010) 114, 62–73
 2010 The Authors
Greengard 2001; Flores-Hernandez et al. 2002; Seamans and
Yang 2004). However, emerging evidence indicates that D1
can also activate other types of G proteins, thereby activating
Ca2+ and protein kinase C (PKC) (Chergui and Lacey 1999;
Chen et al. 2004; Neve et al. 2004). In addition, dynamic
trafficking of NMDA receptors to and from the synaptic sites
is increasingly appreciated as a key determinant in synaptic
transmission and plasticity (Wenthold et al. 2003; Nong
et al. 2004), as well as in pathologic states such as
schizophrenia (Lau and Zukin 2007). NMDA receptor
subunits can be directly phosphorylated by serine/threonine
kinases PKA and PKC (Scott et al. 2003; Chen and Roche
2007) or Src family kinases (Salter and Kalia 2004).
Therefore, an important question is how NMDA receptor
trafficking is regulated by DA and what are the roles of
PKA and PKC in the D1-mediated regulation of NMDA
receptor trafficking. In this study, we hypothesized that D1
activation enhances NMDA receptor trafficking through
rapid synaptic insertion of NMDA receptors, which might
be differentially regulated by PKA and PKC. We tested the
effects of PKA and PKC inhibitors on D1-induced traffick-
ing processes of NMDA receptors, including total expres-
sion, surface expression, synaptic insertion, and synaptic
function. We found that although both PKA and PKC
mediate the D1-induced NMDA receptor trafficking, the
phospholipase C (PLC)-PKC-Src pathway is only required
for the surface expression and synaptic insertion of NMDA
receptors.
Experimental procedures
Detailed experimental protocols can be found in the Appendix S1.
Electrophysiology in PFC slices
Rats at P12–30 were deeply anesthetized and the brains were
sliced at 300 lm (Gao et al. 2001). Whole-cell recordings were
conducted in medial PFC and the recordings were conducted at
35C. To record NMDAR mEPSCs, cells were held at )60 mV
in Mg2+-free solution with perfusion of tetrodotoxin (TTX,
0.5 lM), 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-
2,3-dione (NBQX, 20 lM), and picrotoxin (50–100 lM, see
Figure S1). The NMDA receptor-mediated excitatory postsynaptic
currents (EPSCs) were evoked by stimulating layer 2/3 in the
presence of Mg2+ (1 mM), picrotoxin (50–100 lM) and NBQX
(20 lM) at +40 mV. In some cells, NMDA (100 lM) was puff-
applied from a glass pipette (2 MW) and NMDA currents were
recorded at )60 mV under same conditions. The electric signals
were amplified and acquired with pCLAMP 9.2. A typical
NMDA mEPSC with 20–80% rise time 7 ms and 63% decay time
240 ms was selected to create a sample template for detecting
mEPSCs. The frequency (event number) and amplitude of
individual mEPSC events were automatically detected with
Clampfit by using the template. The amplitudes of the evoked
EPSCs were measured by averaging 30 traces from the onset to
peak of EPSC.
Neuronal cultures and treatment schedules
Neurons at 16–18 days in vitro were treated for 10 min with
SKF-81297 (1 lM). For inhibitor and antagonist experiments, cells
were pre-incubated in the following drugs (Sigma, St. Louis, MO,
USA) and then co-applied with SKF-81297 at the indicated times
and concentrations: KT5720 (20 min, 5 lM), Go6983 (10 min,
20 lM), SCH-23390 (10 min, 10 lM), U73122 (10 min, 10 lM),
4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine
(PP2) (10 min, 10 lM) and inactive structural analogue PP3
(10 min, 10 lM).
Immunocytochemical analysis
(i) Immunostaining of total protein: Immunocytochemical analysis
was performed according to established protocols (Glynn and
McAllister 2006). Briefly, coverslips were fixed with methanol for
10 min followed by permeabilization for 5 min in 0.25% Triton
X-100. Primary antibodies were visualized with FITC- or Cy3-
conjugated secondary antibodies (1 : 500–1 : 1000). The specificity
of all of these antibodies has been demonstrated previously and was
rechecked (see Figure S2). (ii) Surface labeling: We labeled surface
NMDA receptor (NR) 2B using an NR2B N-terminal antibody
(Zymed Laboratories Inc., South San Francisco, CA, USA). The
labeling was performed as previously described (Lu et al. 2001).
Live cultures were incubated with antibody for 30 min. Cells were
then fixed for 15 min, blocked with 5% donkey serum for 60 min,
and incubated with secondary antibody conjugated to FITC for
60 min under non-permeant conditions. (iii) Receptor insertion
assay: The rate of NR2B insertion is determined by pre-blocking
existing surface receptors with primary antibody and non-conju-
gated secondary antibody, bringing cells to 20–22C to allow
receptor insertion, and then detecting newly inserted receptors with
a second round of immunostaining (Lu et al. 2001).
Image analysis
All groups were analyzed simultaneously using cells from the same
culture preparation. For each experimental group, cells from at least
three different wells were used, and approximately five cells from
each well were analyzed. Processes located about 1 soma diameter
from the soma were selected for analysis. Immunocytochemical
quantification was performed using ImageJ software (Glynn and
McAllister 2006).
Results
D1 activation potentiates NMDA receptor-mediated
mEPSCs in PFC pyramidal neurons
We first recorded NMDA mEPSCs from layer V pyramidal
neurons in medial PFC in the presence of the sodium channel
blocker TTX (0.5–1 lM), a-amino-3-hydroxy-5-methylisox-
azole-4-propionate (AMPA) receptor antagonist NBQX
(20 lM), and GABAA receptor antagonist picrotoxin (50–
100 lM) under conditions of zero-Mg2+ with membrane
potential held at )60 mV. After baseline recording for 5–
10 min (Fig. 1), we tested the effect of dopamine D1 agonist
SKF-81297 on the mEPSCs. Bath application of SKF-81297
(1 lM) resulted in a significant potentiation of mEPSCs. As
 2010 The Authors
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shown in Fig. 1(a–d), both frequency and amplitude of
NMDAR mEPSCs were significantly increased during and
after washing out of SKF-81297 (n = 6, p < 0.05 for both).
The NMDA mEPSCs were effectively blocked by NMDA
receptor antagonist (2R)-amino-5-phosphonovaleric acid;
(2R)-amino-5-phosphonopentanoate (APV, 50 lM, data not
shown). Under conditions of zero-Mg2+, both frequency and
amplitude of mEPSCs appeared to be stable, without
significance, in the absence of SKF-81297 (n = 4;
p > 0.05, see Figure S1). To confirm the D1 action, D1
antagonist SCH-23390 (10 lM) was administered for 5 min
and then SCH-23390 and SKF-81297 were co-applied for
10 min. SCH-23390 itself exhibited no significant effects on
the NMDA mEPSCs (data not shown). Under this condition,
SCH-23390 effectively blocked the potentiation of NMDA
mEPSCs caused by SKF-81297 in both frequency and
amplitude (n = 6; p > 0.05, Fig. 1e). In another set of
experiments, we recorded the AMPA receptor-mediated
mEPSCs at )60 mV in the presence of (2R)-amino-5-
phosphonovaleric acid; (2R)-amino-5-phosphonopentanoate
(APV), TTX, and picrotoxin. Under this condition, we found
the neither frequency nor amplitude of the AMPA mEPSCs
was changed by D1 agonist SKF-81297 (1 lM) (n = 6,
p > 0.05, Figure S3).
Next, we determined which NMDA receptor subunits
are involved in D1-mediated regulation of NMDA mE-
PSCs. Bath application of specific NR2B antagonist
ifenprodil (3 lM), which preferentially inhibits NR1/
(a) (b)
(c) (d)
(f)
(e)
Fig. 1 D1 activation enhances NMDA receptor-mediated synaptic
responses. (a) An example of NMDA mEPSC recorded at )60 mV in
zero-Mg2+ solution. The NMDA mEPSCs were clearly detectable
under the control condition. (b) The NMDAR mEPSCs from the same
cell in panel (a) were significantly increased by D1 agonist SKF-81297
(1 lM). (c) Time course showing the significant increase of NMDA
mEPSC numbers (n = 6, p < 0.01). Insets denote the average traces
in the marked periods. (d) Summary graphs show that the amplitudes
of NMDAR mEPSCs were significantly increased during and after
washing out of SKF-81297 (n = 6, *p > 0.05). (e) SKF-81297-induced
changes in mEPSC frequency and amplitude were prevented by pre-
treatment with D1 antagonist SCH-23390 (10 lM, n = 6, p > 0.05).
(f) Bath application of specific NR2B antagonist ifenprodil (3 lM)
effectively blocked the potentiation of NMDA mEPSCs induced by
SKF-81297 (n = 6; **p < 0.01).
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NR2B channels (IC50 = 0.34 lM) (Williams 1993; Tovar
and Westbrook 1999), effectively blocked the potentiation
of NMDA mEPSCs caused by SKF-81297 (Fig. 1f, n = 6;
p < 0.05). These data suggest that D1-mediated potentiation
of NMDA mEPSCs mainly depends on NR1/NR2B,
although NR1/NR2A cannot be excluded. Taken together,
these data indicate that D1 activation potentiates NMDA
mEPSCs in PFC and the D1 agonist is likely to initiate an
intracellular signal pathway to strengthen synaptic trans-
mission.
D1 activation enhances NMDA-induced current and NMDA
receptor-mediated EPSCs in PFC slices
Either pre- or post-synaptic mechanisms could be responsible
for the potentiation of NMDA mEPSCs by SKF-81297. To
differentiate between these possibilities, we directly exam-
ined SKF-81297 effect on NMDA-induced current. NMDA
(100 lM) was applied every 90 s for 2 s through a glass
pipette (2 MW) to elicit NMDA current in the presence of
Mg2+ (1 mM), TTX (0.5 lM), NBQX (20 lM), and picro-
toxin (50 lM) at )60 mV. After application of SKF-81297
(1 lM), NMDA-induced current was gradually increased
(Fig. 2a). The maximal amplitude of NMDA current
increased by 50.4 ± 11.41% in SKF-81297 (n = 5;
p < 0.01; Fig. 2b). Furthermore, we examined the EPSC
response to paired pulses, a measure that is exquisitely
sensitive to transmitter release. As shown in Fig. 2(c),
NMDA EPSCs were elicited by stimulating intracortical
fibers in layer 2/3 with two successive stimuli of identical
strength at an interval of 100 ms (10 Hz) before and after
application of SKF-81297. Although the amplitudes of
both the first and the second EPSCs were increased by
SKF-81297 (Fig. 2d), the ratio of paired pulses was
slightly decreased without significant difference (n = 7,
p > 0.05; Fig. 2e). In addition, no significant difference in
amplitude variability was found, as shown in analysis of
coefficiency of variation (Fig. 2f). These results suggest that
the effect of D1 on NMDA mEPSCs is very likely
attributable to the changes of post-synaptic NMDA recep-
tors, although altered pre-synaptic glutamate release cannot
be completely excluded.
D1 regulation of NMDA mEPSCs involves both PKA and PKC
signaling pathways
D1 activation-induced enhancement of NMDA responses
can be mediated by a number of redundant and cooperative
signaling cascades (Seamans and Yang 2004; Cepeda and
Levine 2006). The most prominent action is through the
activation of D1 receptor-mediated intracellular cAMP/PKA/
DARPP-32 cascade (Blank et al. 1997; Cepeda et al. 1998;
Snyder et al. 1998; Flores-Hernandez et al. 2002). Previous
studies have also shown that PKC plays critical roles in the
D1-NMDA interactions (Chergui and Lacey 1999; Chen
et al. 2004). In order to explore the signaling pathway
involved in the D1-mediated enhancement of NMDA
currents, we first bath-applied PKA or PKC inhibitor to
examine its effect in NMDA mEPSCs. After baseline
recording, we pre-treated with PKA inhibitor KT5720
(5 lM) or H89 (20 lM), or PKC inhibitor Go6983
(20 lM), respectively, for 5 min, and then administered
one of these drugs with SKF-81297 (1 lM) for 10 min. As
shown in Fig. 3(a), the D1-mediated effects on the fre-
quency of NMDA mEPSCs were partially but nonetheless
significantly blocked by either PKA or PKC inhibitor
(p < 0.05 vs. control and p < 0.01 vs. SKF only). On the
other hand, these drugs not only completely blocked the
effects of SKF-81297 (p < 0.01 for all) but also induced
slight decrease of mEPSC amplitudes in PKA inhibitor
KT5720 (but not H89) and PKC inhibitor Go6983. The
(a) (b)
(c) (d)
(e) (f)
Fig. 2 SKF-81297 potentiates the mEPSC through effects on the
NMDA receptors in the post-synaptic site. (a and b) Representative
traces of the inward current (at )60 mV) induced by puff-applied
NMDA (100 lM, every 2 s for 90 s) in the presence of TTX (0.5 lM),
NBQX (20 lM) and picrotoxin (100 lM). The NMDA-induced currents
were significantly potentiated by bath-applied SKF-81297 (1 lM), with
maximum amplitude increased by 50.4 ± 11.4% (n = 5, **p < 0.01).
(c) Sample traces showing the effects of D1 on NMDA EPSCs evoked
by stimulating layer 2/3 with a paired-pulse stimulation (inter-stimulus
interval = 100 ms or 10 Hz) in the presence of picrotoxin (100 lM)
and NBQX (20 lM) with membrane potential held at +40 mV. After
5 min stable baseline recording, SKF-81297 (1 lM) was bath-applied
to the PFC slices. (d) Summary histogram showing that the amplitude
of the first NMDA EPSC was significantly increased by SKF-81297
application (n = 7, *p < 0.05). (e and f) The paired-pulse ratio and
coefficient of variation of the NMDAR EPSCs were unaltered by
SKF-81297 (p > 0.05 for both).
 2010 The Authors
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reason for this discrepancy is unknown. The mEPSC
frequency changes do not follow the same pattern with
the changes in amplitudes, but were consistent with several
previous studies that have also reported a slight decrease of
EPSC amplitude under similar conditions (Huang and
Kandel 1995; Chergui and Lacey 1999; Smith et al.
2005). To further investigate the role of PKA in the
enhancement of NMDA currents, we included a membrane-
impermeant PKA inhibitor peptide fragment (PKI6–22)
amide (20 lM) in the recording pipette in one set of
experiments, Dialysis with PKI6–22 significantly blocked
the SKF-induced changes in the NMDA mEPSC frequency
and amplitude (n = 6, p < 0.05, Fig. 3a). This result was
consistent with a previous study (Smith et al. 2005) but
differed from another report (Chen et al. 2004). In addition,
neither frequency nor amplitude of NMDA mEPSCs was
affected by PKC inhibitor or PKA inhibitor administered
alone without SKF (n = 6, p > 0.05, Fig. 3b). These data
suggested that not only PKA, PKC is also involved in the
D1-induced regulation of NMDA currents, consistent with
previous reports (Neve et al. 2004; Seamans and Yang
2004; Gu et al. 2007). It is therefore possible that PKA and
PKC coordinately mediate the D1 effects on NMDA
receptors (Scott et al. 2003; Chen and Roche 2007).
D1-mediated increase of dendritic localization of NMDA
receptors depends on PKA but not PKC signaling
To directly address the role of D1 activation on NMDA
receptor trafficking, we treated cultured PFC neurons with or
without D1 agonist SKF-81297 and measured the cluster
number and fluorescence intensity of NR2B subunits.
Because efforts to identify antibodies that are capable of
labeling surface NR1 and NR2A subunits were unsuccessful
(Hallett et al. 2006) (Li et al., unpublished observations) and
NR2B subunits are mainly regulated by D1 activation (see
Fig. 1f) (Gao and Wolf 2008), we focused our effort on
NR2B. Treatment with SKF-81297 (1 lM) for 10 min led to
significant increase of dendritic localization of NR2B
subunits (Fig. 4(a–l) and m) (cluster numbers: 39.1 ± 1.09
in control vs. 65.4 ± 1.07 in SKF-81297, n = 20, p < 0.05).
D1 antagonist SCH-23390 (10 lM) blocked the effect of
SKF-81297 on NMDA receptors (cluster number: 32.44 ±
1.32, n = 20; p < 0.01 compared with the SKF-81297
group). D1 activation by SKF-81297, however, exhibited
no alterations in cluster number or fluorescence intensity of
postsynaptic density-95 (PSD-95), a scaffold post-synaptic
protein closely associated with NMDA receptors (see
Figure S4). Interestingly, inclusion of PKA inhibitor KT5720
(5 lM), but not PKC inhibitor Go6983 (20 lM), effectively
blocked the D1 effect on total NR2B expression (Fig. 4m,
cluster numbers: SKF + PKA inhibitor, 42.7 ± 6.1, n = 20,
p > 0.05; SKF + PKC inhibitor, 54.2 ± 9.8, n = 20,
p < 0.05). These data suggest that PKA, but not PKC,
mediated the D1 activation-induced increase of total NR2B
subunits at the neuronal dendrites.
Both PKA and PKC mediate D1-induced increase of surface
expression of NMDA receptors
To directly measure the effect of D1 activation on the surface
expression of NMDA receptors, neurons treated with SKF-
81297 were labeled with an antibody against the extracellular
N-terminal region of NR2B. Using the surface labeling
method (Hallett et al. 2006), control neurons stained under
non-permeabilizing conditions showed surface staining for
endogenous NR2B in a punctate pattern that was expressed
on the dendrites (Fig. 5a,b,a’ and b’). Treatment with SKF-
81297 increased the NR2B surface labeling on PFC neuronal
dendrites, measured by either the NR2B cluster number
(a) (b)
Fig. 3 D1 agonist-induced increase of NMDA-mEPSCs was attenu-
ated by PKA inhibitor and PKC inhibitor. (a) The SKF-81297-induced
potentiation of both NMDA mEPSC frequency and amplitude was
significantly decreased by co-application of PKA inhibitor H89 (20 lM),
KT5720 (5 lM), or PKC inhibitor Go6983 (20 lM) with SKF-81297
(1 lM) (n = 6, *p < 0.05, **p < 0.01). Dialysis with PKA inhibitory
peptide PKI6–22 also significantly blocked the SKF-induced changes
in the NMDA mEPSC frequency and amplitude (n = 6, p < 0.05). (b)
Neither frequency nor amplitude of NMDA mEPSCs was affected by
PKA inhibitor H89, KT5720, or PKC inhibitor Go6983 administered
alone without SKF (n = 6, p > 0.05).
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(control: 15.2 ± 0.6, n = 12; SKF: 20.6 ± 0.9, n = 12,
p < 0.01) or fluorescence intensity (p < 0.01) (Fig. 5c). We
further tested the signaling pathways required in the
increased NR2B cell surface labeling induced by D1
activation. Previous studies suggested that PKA mediates
GluR1 trafficking/surface expression (Snyder et al. 2005;
Gao et al. 2006; Man et al. 2007; Serulle et al. 2007) but not
NMDA receptors (Gao and Wolf 2008). In contrast, long-
term potentiation leads to rapid surface expression of
NMDARs but not AMPA receptors in a PKC- and Src-
family-dependent manner (Grosshans et al. 2002). We
therefore wondered whether PKA and PKC play different
roles in the D1-mediated trafficking of NMDA receptors.
Consistent with a role of cAMP/PKA in D1 receptor
signaling, inclusion of PKA inhibitor KT5720 (5 lM)
effectively blocked the effect of SKF-81297 (1 lM) on
surface NR2B expression (cluster numbers: control 16.6 ±
1.2; SKF 22.4 ± 1.8; SKF + SCH 17.6 ± 2.1; SKF + PKA
inhibitor 17.8 ± 0.5; n = 12; p > 0.05 for all comparisons,
Fig. 5c). In the cortical and hippocampal neurons, the PKC
pathway is known to regulate NMDA receptor function (Lan
et al. 2001; Grosshans et al. 2002; Salter and Kalia 2004;
Lin et al. 2006), although it is unknown whether this
pathway also plays a role in D1 modulation of NMDA
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
(m)
Fig. 4 D1 activation increases total NR2B clusters in permeabilizing
conditions. (a–l), PFC neurons at 16 days in vitro (DIV 16) were
treated with vehicle (a, d, g, j), SKF-81297 (1 lM) (b, e, h, k) or SKF-
81297 in the presence of SCH (10 lM) (c, f, i, l), respectively, and
double labeled for endogenous NR2B (green) and PSD-95 (red)
(scale bar = 5 lm). (m) Quantification of total NR2B immunofluo-
rescence staining. SKF-81297 significantly increased total NR2B
puncta number and fluorescence intensity compared with control
(n = 20, *p < 0.05, **p < 0.01). PKA inhibitor KT5720 (5 lM), but not
PKC inhibitor Go6983 (20 lM), completely blocked D1 effect on
NR2B cluster numbers and fluorescence intensity (n = 20,
**p < 0.01).
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receptors because D1 signaling is traditionally coupled to
cAMP/PKA, not PKC. When PKC inhibitor Go6983
(20 lM) was included in the SKF-81297 treatment, D1
activation no longer enhanced the surface labeling of NR2B
clusters (17.9 ± 1.1, n = 12, p > 0.05; Fig. 5c). Neither
PKA inhibitor KT5720 nor PKC inhibitor Go6983 admin-
istered alone affected the cell surface expression of NR2B
(Fig. 5d). PLC can activate PKC, which in turn activates Src
in hippocampal neurons, so we further tested the requirement
of PLC and Src family kinases. In these experiments, the
cluster numbers increased from 17.1 ± 0.8 in control to
23.7 ± 0.8 in SKF-81297 (n = 12; Fig. 5e). Both the PLC
inhibitor U73122 (10 lM) and Src family kinase inhibitor
PP2 (10 lM) blocked the D1 effect (SKF + PLC inhibitor,
17.7 ± 0.7, p > 0.05; SKF + PP2, 16.8 ± 0.9, p > 0.05,
n = 12). Conversely, the inactive structural analogue PP3
(10 lM) did not block the D1 effect (22.5 ± 1.1, n = 12,
p < 0.01).
Both PKA and PKC mediate D1-induced increase of new
insertion of NMDA receptors
An increase in surface expression of NMDA receptors could
be because of increased insertion or decreased internalization
of NMDA receptors or both. To directly address whether D1
activation affects the rate of NMDA receptor insertion, we
selectively labeled newly inserted NR2B using a pre-blocking
method (see Appendix S1) (Lu et al. 2001). Neurons treated
with SKF-81297 (1 lM) showed significantly higher levels of
newly inserted NR2B than control cultures, demonstrating
that D1 receptor stimulation increased the rate of NR2B
insertion (Fig. 6). Using this approach, we examined the role
of PKA and PKC signaling in D1 activation-induced insertion
of NR2B receptors. We observed that both PKA and PKC
inhibitors (5 lM KT5720 and 20 lM Go6983, respectively)
significantly blocked the D1 effect on NR2B insertion (n = 12,
cluster numbers: control, 10.3 ± 0.4; SKF, 14.4 ± 0.6,
p < 0.01; SKF + PKA inhibitor, 10.7 ± 0.2, p > 0.05; SKF
(a) (b)
,
(a′)
(c) (d)
(e)
(b′)
Fig. 5 D1-mediated increase in cell surface
expression of NR2B is mediated by both
PKA and PLC-PKC-Src pathways. (a and b,
a’ and b’) Neurons treated with various
chemicals were stained with anti-N-terminal
NR2B under non-permeabilized conditions
to label cell surface NR2B (scale
bar = 10 lm). (c) Quantitative analysis from
40-lm dendrites of immunostained neurons
showing a significant increase in surface
NR2B clusters and fluorescence intensity
in SKF-81297-treated neurons (n = 12,
*p < 0.05, **p < 0.01). The significant in-
crease in surface NR2B clusters and fluo-
rescence intensity in SKF-81297-treated
neurons was blocked by D1 antagonist
SCH-23390 (10 lM), PKA inhibitor KT5720
(5 lM), and PKC inhibitor Go6983 (20 lM),
respectively (n = 12, p > 0.05). (d) In con-
trast, neither PKA nor PKC inhibitor
administered alone affected cell surface
NR2B expression (n = 6 for each treatment,
p > 0.05). (e) D1-mediated increase in
NR2B surface expression was blocked by
PLC inhibitor (U73122 10 lM, n = 12,
p > 0.05) and Src kinase inhibitor (PP2,
10 lM, n = 12, p > 0.05) but not by inactive
structural analogue PP3 (10 lM, n = 12,
**p < 0.01).
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+ PKC inhibitor, 11.4 ± 0.4, p > 0.05) (Fig. 6g). Interest-
ingly, neither PKA inhibitor (11.0 ± 0.4, n = 12) nor PKC
inhibitor Go6983 (11.2 ± 0.5, n = 12) used alone affected
NR2B insertion at the basal level (Fig. 6g). Furthermore, PLC
inhibitor U73122 (10 lM) or Src family kinase inhibitor PP2
(10 lM), but not its inactive analogue PP3 (10 lM),
abolished the enhancement of NR2B insertion induced by
D1 activation (n = 12, cluster numbers: control, 11.5 ± 0.5;
SKF, 16.1 ± 0.6, p < 0.01; SKF + PLC inhibitor, 12.4 ± 0.8,
p > 0.05; SKF + PP2, 12.3 ± 0.5, p > 0.05; SKF + PP3,
15.9 ± 0.3, p < 0.01) (Fig. 6h). This finding suggests that the
D1-mediated synaptic insertion of NR2B subunits requires
both PKA and PLC-PKC-Src pathways and the trafficking of
NR2B is responsible to the D1 enhancement of NMDA
receptor function.
The newly inserted NMDA receptors induced by D1
activation are localized on synaptic site and are functional
NMDA receptors need to be on the cell surface to receive the
glutamate binding. Our data, as well as others (Hallett et al.
2006; Gao and Wolf 2008), indicated that D1 receptor
activation leads to rapid trafficking of NMDA receptor
subunits and increases surface expression of both NR1 and
NR2B subunits in the dendrites of cultured neurons. It
remains, however, unknown whether the increased surface
receptors are functional or not because increase of NMDA
receptors on the cell surface can be caused by increased
receptors on synaptic sites or extrasynaptic sites. Only an
increase in NMDA receptors on synaptic sites can strengthen
the function of newly inserted receptors. Therefore, D1-
mediated potentiation of NMDA mEPSCs could be because
(a) (b)
(c) (d)
(e)
(g) (h)
(f)
Fig. 6 D1-mediated NR2B insertion to plasma membrane is PLC-
PKC-Src pathway dependent. (a–f) NR2B newly inserted into cell
membrane under various conditions (scale bar = 10 lm). D1
enhancement of NR2B insertion into cell membrane appeared to de-
pend on PKA (d) and PKC (f). (g) Summary histogram showing that D1
agonist SKF-81297 significantly increased NR2B insertion into cell
membrane (n = 12, **p < 0.01). PKA inhibitor KT5720 (5 lM) and
PKC inhibitor (Go6983, 20 lM) blocked the effects of SKF-81297 on
NR2B expression (n = 12 in each condition, p < 0.05; g). (h) D1
receptor-mediated NR2B insertion was also obstructed by coapplica-
tion of PLC inhibitor U73122 (10 lM, n = 12, p > 0.05) and Src
inhibitor PP2 (10 lM, n = 12, p > 0.05) but not by inactive analogue
PP3 (10 lM, n = 12, *p < 0.05, **p < 0.01).
 2010 The Authors
Journal Compilation  2010 International Society for Neurochemistry, J. Neurochem. (2010) 114, 62–73
D1-mediated rapid trafficking of NMDA receptors | 69
of NMDA receptors undergoing translocation from an
intracellular location to the synapses. We tested this
assumption by using MK-801, an activity-dependent and
irreversible NMDA receptor antagonist (Rosenmund et al.
1993). Previous studies showed that MK-801 could only
block the synaptic NMDA receptors that opened in response
to synaptically released glutamate and once the receptors are
blocked, they become dysfunctional and the channel prop-
erties are irreversible (Tovar and Westbrook 2002). We took
the advantage of these properties to examine whether D1
strengthens NMDA current by translocating NMDA recep-
tors to synapses. The NMDAR-mediated EPSCs were
evoked by stimulating layer 2/3 with a single pulse
(0.1 ms, 10–100 lA, 0.1 Hz) in the presence of picrotoxin
(50–100 lM) and NBQX (20 lM) at +40 mV. After 5 min
stable recording, MK-801 (20 lM) was bath-applied to the
PFC slices. As shown in Fig. 7(a), the NMDA EPSCs were
progressively and completely blocked after 10 min. The
NMDA EPSCs were at an almost undetectable level in the
control group even 20 min after washout of the unbound
MK-801 in the absence of stimulation. In contrast, when
SKF-81297 (1 lM, 10 min) was bath-applied during the
washing period, a clear recovery of NMDA EPSCs in
response to the 0.1-Hz stimulation was observed (Fig. 7a).
The amplitude recovery of NMDA EPSCs in the SKF-
81297-treated neurons was significantly greater than that in
controls (6.54 ± 6.89% in control vs. 43.4 ± 2.55% in SKF-
81297, n = 6, p < 0.01, Fig. 7b). Consistently, the recovery
of NMDA EPSCs induced by SKF-81297 was blocked by
co-application of SKF with either PKA inhibitor KT5720 or
NR2B inhibitor ifenprodil (recovered only by 17.1 ± 2.16%
and 15.1 ± 3.62%, respectively, n = 6 for each drug and
p < 0.01 for both, Fig. 7b). These data further suggest that
the newly inserted NR2B-containing NMDA receptors
induced by D1 activation are likely to be translocated from
intracellular or extrasynaptic sites to the synaptic membrane
where they become functional.
Discussion
This study has identified that rapid NMDA trafficking and
synaptic insertion underlie the D1-induced enhancement of
NMDA receptors. Importantly, we show that both PKA and
PKC signaling pathways play important roles in the regula-
tory process. However, it appears that, although both PKA
and PKC mediate the D1 activation-induced enhancement of
NMDA receptors, the PLC-PKC-Src pathway is only
required for surface expression and new synaptic insertion
of NMDA receptors.
We found that D1 receptor activation enhanced both
frequency and amplitude of NMDA mEPSCs in PFC
pyramidal neurons. Although the frequency of mEPSCs
was previously interpreted as being of pre-synaptic origin,
the change of mEPSC frequency could be directly attribut-
able to alterations of post-synaptic receptors (Smith et al.
2005). In fact, after washing D1 agonist, the potentiated
mEPSCs did not return to baseline and, instead, were even
further facilitated. One possibility is that SKF-81297 primed
the intracellular signal pathway(s) to potentiate receptor
trafficking, and once it was triggered, it would not depend
on agonist itself (Seamans et al. 2001). This assumption,
however, depends on the D1 action on post-synaptic
receptors. Indeed, D1 agonist SKF-81297 enhanced puff
(a)
(b)
Fig. 7 D1 promotes the recovery of NMDAR currents by translocating
intracellular NMDA receptors to the synapse. (a) The NMDA EPSCs
were evoked by stimulating layer 2/3 in the presence of picrotoxin
(100 lM) and NBQX (20 lM) at +40 mV. After 5 min stable recording,
MK-801 (20 lM) was bath-applied to PFC slices for 10 min to
progressively block the NMDA EPSCs. The stimulation was stopped
for 20 min to wash out the residual MK-801 after the EPSCs were
completely and irreversibly blocked. The NMDA EPSCs were at an
almost undetectable level under control condition but were significantly
increased when SKF-81297 (1 lM) was bath-applied for 10 min during
the washout period. Co-application SKF-81297 (1 lM) with either PKA
inhibitor KT5720 (5 lM) or NR2B antagonist ifenprodil (3 lM) blocked
the recovery of NMDA EPSCs induced by SKF-81297. (b) Summary
histogram showing that SKF-81297 significantly promoted the recov-
ery of NMDA EPSCs (n = 6, **p < 0.01) and this effect was blocked by
either PKA inhibitor or NR2B antagonist.
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NMDA-induced current and evoked NMDA EPSCs, but did
not change the paired-pulse ratio and coefficient of variation
of the evoked NMDA-EPSCs (Zheng et al. 1999; Chen et al.
2004), indicating a direct post-synaptic effect. The increased
total NR2B subunits and clusters of both NR1 and NR2B in
the neuronal dendrites also provided direct evidence of post-
synaptic receptor change. Furthermore, the AMPA mEPSCs
were unchanged by low concentration of SKF-81297 (1 lM)
under our recording conditions. At relative high concentra-
tions, dopamine through D1 activation actually produced a
decrease in AMPA EPSCs, indicating a reduction of
glutamate release at pre-synaptic site (Nicola and Malenka
1997; Gao et al. 2001; Seamans et al. 2001; Ding et al.
2003). Although it remains unclear how pre-synaptic reduc-
tion of glutamate release would reconcile with post-synaptic
trafficking of AMPA and NMDA receptors, it is proposed
that by increasing the NMDA EPSCs, yet slightly reducing
release, D1 activation may selectively enhance sustained
synaptic inputs (Seamans et al. 2001).
NMDAR trafficking presents a dynamic and powerful
mechanism for the regulation of synaptic transmission and
plasticity (Wenthold et al. 2003; Lau and Zukin 2007).
Previous studies indicated that the D1-induced increase of
NR2B expressions is possibly initiated by phosphorylation of
existing receptors (Dunah and Standaert 2001; Hallett et al.
2006; Gao and Wolf 2008; Tong and Gibb 2008). In the PFC
neurons, D4 activation decreased NR1 surface expression
(Wang et al. 2003), whereas D1 receptors facilitated the
trafficking of NMDA receptors (Chen et al. 2004; Gao and
Wolf 2008). Our data provided novel evidence that D1-
induced enhancement of NMDA receptor function depends
on rapid insertion of NMDA receptors to the synaptic
surface. Most importantly, we found that the D1 receptor-
mediated increase in NMDA receptor trafficking depends on
both PKA and PKC/Src but their roles appear to be different
in the regulatory process.
Although both serine kinases PKA and PKC and tyrosine
kinase Src/Fyn can regulate NMDA receptor trafficking (Lan
et al. 2001; Scott et al. 2003; Salter and Kalia 2004; Chen
and Roche 2007), it is unknown how PKA and PKC regulate
the trafficking of NMDA receptors induced by D1 activation.
In this study, we defined a signaling cascade from PLC to
PKC to Src family kinase that is important for the trafficking
of NMDA receptors after D1 activation. The requirement of
PLC/PKC/Src signaling cascade in the enhanced trafficking
of NMDA receptors after D1 activation is intriguing because
D1 receptor is well known to activate the classical D1/cAMP/
PKA/DARPP-32 pathway (Blank et al. 1997; Cepeda et al.
1998; Snyder et al. 1998; Flores-Hernandez et al. 2002). In
addition, although our results showed that PKA inhibitor
blocked the D1-induced changes of surface expression and
synaptic insertion of NR2B subunits, its role in these
trafficking processes could be not be confirmed or excluded
because PKA inhibitor also blocked the D1-induced changes
in total NR2B expression. As PKC inhibition did not block
the D1-induced increase in total NR2B at dendritic spines,
but nonetheless blocked the surface insertion of NMDA
receptors, we speculate a two step process: first is the
increase of NMDA receptors underneath the dendritic spines
(which is dependent on PKA) followed by the insertion of
NMDA receptors into the spines (which is dependent on
PKC). The first step could involve local protein synthesis,
and/or PKA-dependent NMDA receptor re-distribution
(Crump et al. 2001; Smith et al. 2005). This assumption,
however, needs further exploration. Indeed, it has been
shown that although PKA mediates the effect of D1
stimulation on the surface expression of AMPA receptors
(Mangiavacchi and Wolf 2004; Smith et al. 2005; Sun et al.
2005, 2008; Gao et al. 2006), PKA activation was not
sufficient to alter the surface expression of NMDA receptors
in the cultured PFC neurons (Chen et al. 2004; Gao and Wolf
2008). In contrast, our data suggest that the D1/PLC/PKC
pathway may mediate the delivery of NMDA receptors,
likely involved in surface expression and new insertion of
NMDA receptors only, in consistence with previous studies
(Chergui and Lacey 1999; Chen et al. 2004; Gao and Wolf
2008). Therefore, it is possible that PKA activation targets
NMDA receptors to synapses (Crump et al. 2001), whereas
PKC activation delivers NMDA receptors to the neuronal
surface (Lan et al. 2001; Fong et al. 2002; Grosshans et al.
2002).
Furthermore, we have provided evidence that the process
of new synaptic insertion of NR2B subunits on the cell
surface triggered by D1 stimulation appeared to be very rapid.
Indeed, a recent study showed that subunit composition of
synaptic NMDA receptors was extremely fast at neonatal
synapses (Bellone and Nicoll 2007), as rapid as that seen with
AMPA receptors (Smith et al. 2005; Bellone and Nicoll
2007). This rapid potentiation of NMDA receptor trafficking
in the dendrites of prefrontal neurons by D1 activation at very
low (presumably optimal) concentration will have immediate
effects on the integrative capacity of the synapse and can lead
to important functional outcomes (Bellone and Nicoll 2007),
particularly for working memory and other cognitive func-
tions in the PFC. Indeed, D1 antagonists have deleterious
effects on the performance of working memory tasks in the
primate PFC (Williams and Goldman-Rakic 1995). The lack
of D1 receptor sequestration in response to agonists because
of its heteromerization with NMDA receptors would prolong
dopamine’s action on synaptic strength (Fiorentini and
Missale 2004) and cognitive functions. In addition, both
dopaminergic dysfunction and glutamatergic hypofunction
are important for the development and symptomatology of
some mental diseases such as schizophrenia and drug
addiction. The novel NMDA trafficking pathway identified
in the D1 and NMDA receptor interaction is therefore
important for understanding the interaction between dopa-
mine and glutamate in these psychiatric disorders.
 2010 The Authors
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